FAIRFIELD, N.J., Jan. 20 /PRNewswire-FirstCall/ -- Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals, Inc. , today announced the introduction of new LidaMantle(R) Lotion, LidaMantle(R) HC Lotion and CARMOL(R) HC Cream 3 ounce.
LidaMantle(R) Lotion, a topical anesthetic, and LidaMantle(R) HC Lotion, an anti-inflammatory anesthetic, are the newest members of the Doak Dermatologics popular LidaMantle(R) family of products. LidaMantle(R) Lotion and LidaMantle(R) HC Lotion were developed in response to physician demand for formulations that would be suitable for larger area applications. These smooth, easily spreadable therapies can help deliver rapid relief of itch, pain and inflammation of eczema and dermatitis at the first sign of a flare-up.
CARMOL(R)HC, indicated for the treatment of corticosteroid-responsive skin conditions such as atopic dermatitis, mild psoriasis and contact dermatitis, is often prescribed for long-term use. Previously, CARMOL(R)HC was available in a 1 oz. tube only. In response to the need for a more convenient size, Doak is introducing the new 3 oz. tube to last longer and be more cost-effective for patients, providing three times the amount of medication for the same co-pay.
President and CEO Daniel Glassman stated, "Bradley is pleased to offer physicians three new prescribing options for their patients suffering from eczema, dermatitis and psoriasis. Since all three conditions are chronic, and often appear on a large percentage of a patient's skin, Doak is pleased to address physician and patient needs with a larger size of CARMOL(R)HC and easily spreadable LidaMantle(R) Lotion and LidaMantle(R) HC Lotion."
Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company marketing prescription niche therapies to highly targeted physician audiences in the United States and in 34 international markets. Dermatology brands are delivered by the Doak Dermatologics subsidiary and the Kenwood Therapeutics division provides gastroenterology, nutritional and respiratory therapies. Following the strategy "Acquire, Enhance, Grow" the company has achieved success by acquiring and managing the life cycle of brands that fill unmet needs.
Important announcement:
Daniel Glassman will present at the Raymond James & Associates 25th Annual Institutional Investors Conference at 11AM Monday, March 1, 2004 Room G, at the Hyatt Regency Grand Cypress in Orlando, FL.
Brent Lenczycki, CFO, will present at the Wall Street Analyst Forum scheduled for March 1-3, 2004 at the Roosevelt Hotel in New York City.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com/
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Except for historical and factual information, this press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates, launches of new products, market acceptance of products, and predictions of future financial performance. All forward-looking statements are based on assumptions made by Bradley based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. These statements are subject to numerous risks and uncertainties, many of which are beyond Bradley's control, including Bradley's ability to maintain CARMOL(R) sales and bear the outcome of related pending litigation and the introduction of new and future competing products, whether branded, or generic, or comparable, effectively purchase or integrate new products into its portfolio or effectively react to other risks described from time to time in Bradley's SEC filings. Further, Bradley cannot predict the impact on its business of any introduction, or future approvals, of generic or therapeutically equivalent or comparable versions of its products or of other competing products. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.